Biocon Biologics and Viatris launch Abevmy in Canada EP News Bureau May 24, 2022 Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…
Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab EP News Bureau Apr 26, 2021 Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…
Biocon Biologics and Viatris get CHMP Nod for Abevmy EP News Bureau Mar 1, 2021 Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth